Milestone Pharmaceuticals (MIST) Price & Analysis

Compare

690 Followers

MIST Stock Chart & Stats

$2.95

-$0.02(-0.90%)

At close: Jan 08 4:00 PM EST

$2.95

-$0.02(-0.90%)

Day’s Range― - ―

52-Week Range$0.63 - $2.77

Previous CloseN/A

Volume143.50K

Average Volume (3M)2.94M

Market Cap

$224.00M

Enterprise Value$167.61M

Total Cash (Recent Filing)$82.58M

Total Debt (Recent Filing)$57.21M

Price to Earnings (P/E)―

Beta2.04

Next Earnings

Mar 31, 2026

EPS Estimate

-0.17

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.12

Shares Outstanding85,169,340

10 Day Avg. Volume3,381,148

30 Day Avg. Volume2,939,107

Financial Highlights & Ratios

PEG Ratio0.07

Price to Book (P/B)11.17

Price to Sales (P/S)0.00

P/FCF Ratio-5.08

Enterprise Value/Market Cap0.75

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-283.13

Enterprise Value/Ebitda-3.12

Forecast

1Y Price Target

$4.50

Price Target Upside52.54% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

EPS Forecast (FY)-0.82

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Financial PositionThe RTW financing, combined with upfront proceeds of $48.7M from the first exercised tranche of MIST's recent July financing, gives cash runway into 1H27.

Market Entry PreparationPlans to launch etripamil include hiring a robust sales team, which indicates strong preparation for market entry.

Regulatory ApprovalThe FDA accepted MIST's CRL response for etripamil in pSVT, suggesting a clear path to approval.

Bears Say

Milestone Pharmaceuticals News

Milestone Pharmaceuticals: Buy Rating Reaffirmed Amid Imminent PDUFA Date and Misunderstood CRL Implications

Analyst Brandon Folkes of H.C. Wainwright reiterated a Buy rating on Milestone Pharmaceuticals, retaining the price target of...

7d ago

MIST

Milestone Pharmaceuticals Reports Q3 2025 Financial Results

Milestone Pharmaceuticals ( ($MIST) ) has released its Q3 earnings. Here is a breakdown of the information Milestone...

30d ago

MIST

Milestone Pharmaceuticals Prepares for CARDAMYST Launch Amid Financial Growth

Milestone Pharmaceuticals ( ($MIST) ) just unveiled an update. Milestone Pharmaceuticals announced its third-quarter financial results and provided...

1M ago

MIST

Milestone Pharmaceuticals: Positioned for Success with Cardamyst’s Potential Approval and Launch

Analyst Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Milestone Pharmaceuticals and keeping the price target...

1M ago

MIST

Milestone Pharmaceuticals reports Q3 EPS (12c), consensus (17c)

“We are approaching our December 13 Prescription Drug User Fee Act date with optimism and excitement for the...

1M ago

MIST

MIST Earnings this Week: How Will it Perform?

Milestone Pharmaceuticals (MIST) is scheduled to report 3rd quarter earnings on 11/12/2025. Regarding Q3 estimates, Wall Street analysts...

1M ago

MIST

Milestone Pharmaceuticals to present new analysis from trials for PSVT

Milestone Pharmaceuticals (MIST) announced that new data analyses surrounding its lead investigational product for the management of paroxysmal...

1M ago

MIST

Milestone Pharmaceuticals initiated with an Overweight at Wells Fargo

Wells Fargo initiated coverage of Milestone Pharmaceuticals (MIST) with an Overweight rating and $4 price target The company...

3M ago

MIST

Milestone Pharmaceuticals Reports Increased Loss Amid R&D Focus

Milestone Pharmaceuticals ( ($MIST) ) has released its Q2 earnings. Here is a breakdown of the information Milestone...

4M ago

MIST

Milestone Pharmaceuticals: Strong Buy Rating Backed by Anticipated Cardamyst Approval and Robust Financial Position

In a report released today, Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Milestone Pharmaceuticals, with...

4M ago

MIST

Milestone Pharmaceuticals Advances CARDAMYST with FDA and Financial Boost

The latest announcement is out from Milestone Pharmaceuticals ( ($MIST) ). Milestone Pharmaceuticals announced that the FDA has...

4M ago

MIST

Milestone Pharmaceuticals reports Q2 EPS (20c), consensus (18c)

“With the FDA’s recent acceptance of our response to the CRL, our team is energized as we work...

4M ago

MIST

Milestone Pharmaceuticals’ Cardamyst NDA Resubmission Boosts Buy Rating Amid FDA Progress

In a report released today, Brandon Folkes from H.C. Wainwright maintained a Buy rating on Milestone Pharmaceuticals, with...

5M ago

MIST

Milestone Pharmaceuticals Announces Public Offering for $48.7M

Milestone Pharmaceuticals ( ($MIST) ) has issued an announcement. On July 11, 2025, Milestone Pharmaceuticals announced an underwritten...

5M ago

MIST

MIST FAQ

What was Milestone Pharmaceuticals’s price range in the past 12 months?

Milestone Pharmaceuticals lowest stock price was $0.63 and its highest was $2.77 in the past 12 months.

What is Milestone Pharmaceuticals’s market cap?

Milestone Pharmaceuticals’s market cap is $224.00M.

When is Milestone Pharmaceuticals’s upcoming earnings report date?

Milestone Pharmaceuticals’s upcoming earnings report date is Mar 31, 2026 which is in 109 days.

How were Milestone Pharmaceuticals’s earnings last quarter?

Milestone Pharmaceuticals released its earnings results on Nov 12, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.164 by $0.044.

Is Milestone Pharmaceuticals overvalued?

According to Wall Street analysts Milestone Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Milestone Pharmaceuticals pay dividends?

Milestone Pharmaceuticals does not currently pay dividends.

What is Milestone Pharmaceuticals’s EPS estimate?

Milestone Pharmaceuticals’s EPS estimate is -0.17.

How many shares outstanding does Milestone Pharmaceuticals have?

Milestone Pharmaceuticals has 85,169,340 shares outstanding.

What happened to Milestone Pharmaceuticals’s price movement after its last earnings report?

Milestone Pharmaceuticals reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.164. Following the earnings report the stock price went up 1.047%.

Which hedge fund is a major shareholder of Milestone Pharmaceuticals?

Currently, no hedge funds are holding shares in MIST

Milestone Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-260.65%

Trailing 12-Months

Asset Growth

6.10%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Milestone Pharmaceuticals (MIST) Earnings & Revenues

Historic Earnings Reports

MIST Stock 12 Month Forecast

Average Price Target

$4.50

▲(52.54% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","-1":"-$1","0.75":"$0.75","2.5":"$2.5","4.25":"$4.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.75,2.5,4.25,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.69,2.8676923076923075,3.0453846153846156,3.223076923076923,3.4007692307692308,3.5784615384615384,3.756153846153846,3.933846153846154,4.111538461538462,4.28923076923077,4.466923076923077,4.644615384615385,4.822307692307692,{"y":5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.69,2.829230769230769,2.9684615384615385,3.1076923076923078,3.246923076923077,3.3861538461538463,3.525384615384615,3.6646153846153844,3.8038461538461537,3.943076923076923,4.082307692307692,4.2215384615384615,4.360769230769231,{"y":4.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.69,2.790769230769231,2.8915384615384614,2.9923076923076923,3.0930769230769233,3.193846153846154,3.2946153846153847,3.3953846153846152,3.496153846153846,3.596923076923077,3.6976923076923076,3.7984615384615386,3.899230769230769,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.5,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.36,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.97,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.63,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.76,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.73,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.88,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.43,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.84,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.92,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.69,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >